Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center

PurposeFLAURA2 demonstrated that adding chemotherapy to osimertinib improved overall survival compared with osimertinib monotherapy in metastatic epidermal growth factor receptor-mutated (EGFR-mut) non-small cell lung cancer (NSCLC). Notably, only 60% of patients in the osimertinib monotherapy arm received second-line therapy after discontinuing first-line osimertinib, raising the concern that FLAURA2 did not accurately reflect real-world practices at academic medical centers. We hypothesized…